Background: The cerebellum is essential for intact motor function and has an important role in cognitive and neuropsychiatric processes. It is known that the cerebellum is involved in ALS pathology, but the role of gray matter (GM) and white matter (WM) changes is still unclear.
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Background: The diagnostic value of muscle ultrasound in the diagnosis of amyotrophic lateral sclerosis (ALS) has increased because it can detect fasciculations more reliably than EMG in certain muscle groups (e.g. tongue) as well as it can access certain muscle groups more easily than EMG (e.g. tongue, diaphragm, abdominal muscles). Recently, we have introduced the D50 ALS model which enables the assessment and the comparison of individual ALS disease courses. In this retrospective study we aim to explore the role of muscle ultrasound in clinical routine in relation to ALS progression parameters in a large cohort.
Methods: 4 year ultrasonography data (echo intensity and fasciculation) in 6 muscle groups of 220 ALS patients were related to the onset type, disease duration, ALSFRS-R, its progression rate, D50 (= time [months] taken for ALSFRS-R to drop to 24) and relative D50 (rD50 = calculated value describing individual disease covered in reference to D50). In a patient subset of 23 patients repeated measurements during disease progression were performed to monitor both clinical an ultrasonographic changes over time.
Results: We observed significant differences in echo intensity between slow (D50 > 40 months) and fast (D50 < 20 months) progressive ALS patients and an increase in echo intensity between disease phase I and phase II. Furthermore, we detected a tendency towards a higher Heckmatt Score already in disease phase I in patients with a more aggressive disease course.
Conclusion: Muscle ultrasound has an important diagnostic value in early ALS. Combined with the D50 model of ALS progression, it can aid prognostic stratification which is important for patients planning, inclusion into future clinical trials and the understanding of the underlying pathology.
Acknowledgements: We thank Mandy Arnold and Cindy Höpfner for her excellent patient care and clinical data collection. This study was supported by grants to JG by the BMBF through the E-RARE framework (PYRAMID) and JPND (OnWebDuals) and in collaboration with the German Network for Motoneuron Diseases (MND-NET). Background: Studies using neuromelanin-sensitive-MRI have established the Locus Coeruleus (LC)-to-pons intensity ratio as a biomarker for diagnosis of Parkinson's and Alzheimer's disease. More detailed analysis is needed for exploiting the highest clinical potential of this technique.
Objective: The aim is to determine the location of the highest LCto-pons ratio within the locus coeruleus and develop an easy-to-use tool for clinical application.
Methods: Ten patients diagnosed with various stages of Alzheimer's disease (74.1 ± 3.9 years, range 68-80, 7 females) and ten healthy elderly subjects (72.4 ± 3.1 years, range 68-77, 5 females) participated in the study. Five subsequent slices with a thickness of 2.5 mm were analyzed using the image analysis tool FSL, starting with the first slice below inferior colliculus. The outcome variable was the intensity ratio between maximum values of locus coeruleus and adjacent pontine region.
Results: The section located 10 mm below the inferior colliculus has the highest potential in differentiating between healthy controls and patients, with the intensity-ratio difference between groups of 12.3% and effect size of 1.577. For the cut-off value of 1.09 the sensitivity and specificity values were 100% and 80%, respectively.
Conclusion: We consider the method a promising clinical tool to aid AD diagnosis workup. 
